| 前收市價 | 8.60 |
| 開市 | 8.57 |
| 買盤 | 0.00 x 4000 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 8.55 - 8.76 |
| 52 週波幅 | 5.57 - 11.46 |
| 成交量 | |
| 平均成交量 | 2,758,550 |
| 市值 | 3.186B |
| Beta 值 (5 年，每月) | 0.86 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.62 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2010年11月10日 |
| 1 年預測目標價 | 10.33 |
- Reuters
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals.
ZacksWill Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Reuters
CANADA STOCKS-TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
Canada's main stock index ended flat on Monday, as gains in financials and industrial stocks were offset by losses in healthcare driven by Bausch Health. Investors were cautious ahead of Wednesday's Bank of Canada interest rate decision, when the central bank is expected to hold rates steady, and release new economic growth projections. The Toronto Stock Exchange's S&P/TSX composite index was down 4.08 points, or 0.02%, at 22,260.30.
